About this Research Topic
Prostate cancer is one of the most common malignant diseases in men and the disease is leading cause of cancer-related deaths worldwide. Although there has been development within the field of treatment and therapy for prostate cancer, it remains to have poor prognosis and a low survival rate due to the metastatic nature of the disease and resistance to drug therapies and treatment. Therefore, further novel strategies are required to improve the survival rate for patients.
Prostate-specific membrane antigen (PSMA), a transmembrane zinc metalloenzyme, has been found to be overexpressed in prostate cancer and has advanced levels in metastatic castration-resistance prostate cancer. Various studies have highlighted a relationship between the aggressive state of the disease, Gleason score and the potential to metastasize. Therefore, PSMA has been identified as a novel target for diagnostic development to identify prostate cancer at earlier stages and to provide appropriate treatment options. PSMA radioligand therapy utilising urea-based agents with - and β-particle–emitting radionuclide e.g. Lutetium-177, Actinium-225, Thorium-227, Terbium-161, Lead 212, etc have been identified as a promising approach for hormone sensitive as well as castrate resistant prostate cancer patients.
The aim of this Research Topic is to generate a discussion on how radioligand therapy (RLT) impacts prostate cancer and how it can impact the prognosis and survival rate of the disease. We welcome Original Research Articles, Review Articles and Systematic Reviews dealing with topics like:
-Mechanism of action of PSMA targeting radioligands
-Treatment planning of PSMA RLT
-Clinical and imaging factors (PSMA heterogeneity, clonal heterogeneity) affecting efficacy and therapeutic index of PSMA RLT
-Genetic and molecular factors affecting PSMA RLT efficacy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate-specific membrane antigen (PSMA), a transmembrane zinc metalloenzyme, has been found to be overexpressed in prostate cancer and has advanced levels in metastatic castration-resistance prostate cancer. Various studies have highlighted a relationship between the aggressive state of the disease, Gleason score and the potential to metastasize. Therefore, PSMA has been identified as a novel target for diagnostic development to identify prostate cancer at earlier stages and to provide appropriate treatment options. PSMA radioligand therapy utilising urea-based agents with - and β-particle–emitting radionuclide e.g. Lutetium-177, Actinium-225, Thorium-227, Terbium-161, Lead 212, etc have been identified as a promising approach for hormone sensitive as well as castrate resistant prostate cancer patients.
The aim of this Research Topic is to generate a discussion on how radioligand therapy (RLT) impacts prostate cancer and how it can impact the prognosis and survival rate of the disease. We welcome Original Research Articles, Review Articles and Systematic Reviews dealing with topics like:
-Mechanism of action of PSMA targeting radioligands
-Treatment planning of PSMA RLT
-Clinical and imaging factors (PSMA heterogeneity, clonal heterogeneity) affecting efficacy and therapeutic index of PSMA RLT
-Genetic and molecular factors affecting PSMA RLT efficacy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: prostate cancer, radioligand therapy, treatment, therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
